316 related articles for article (PubMed ID: 23819170)
1. Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
Prescrire Int; 2013 May; 22(138):121. PubMed ID: 23819170
[No Abstract] [Full Text] [Related]
2. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040
[No Abstract] [Full Text] [Related]
3. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
Del Prato S
Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
[TBL] [Abstract][Full Text] [Related]
5. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Göke R; Gruenberger JB; Bader G; Dworak M
Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
[TBL] [Abstract][Full Text] [Related]
6. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
Scherbaum WA
Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
[No Abstract] [Full Text] [Related]
7. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
[TBL] [Abstract][Full Text] [Related]
8. Translating science into clinical practice: focus on vildagliptin in combination with metformin.
Barnett AH
Diabetes Obes Metab; 2009 May; 11 Suppl 2():18-26. PubMed ID: 19385980
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Cai L; Cai Y; Lu ZJ; Zhang Y; Liu P
J Clin Pharm Ther; 2012 Aug; 37(4):386-98. PubMed ID: 22191695
[TBL] [Abstract][Full Text] [Related]
10. Update: vildagliptin for the treatment of Type 2 diabetes.
Garber AJ; Sharma MD
Expert Opin Investig Drugs; 2008 Jan; 17(1):105-13. PubMed ID: 18095923
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic use and adverse events of incretin-related drugs].
Ishikawa M; Yamada Y
Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
[No Abstract] [Full Text] [Related]
12. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
Halimi S; Raccah D; Schweizer A; Dejager S
Curr Med Res Opin; 2010 Jul; 26(7):1647-56. PubMed ID: 20441397
[TBL] [Abstract][Full Text] [Related]
13. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Gallwitz B
Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
[No Abstract] [Full Text] [Related]
14. A case of bullous pemphigoid ınduced by vildagliptin.
Keseroglu HO; Taş-Aygar G; Gönül M; Gököz O; Ersoy-Evans S
Cutan Ocul Toxicol; 2017 Jun; 36(2):201-202. PubMed ID: 27460861
[TBL] [Abstract][Full Text] [Related]
15. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Schweizer A; Dejager S; Bosi E
Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
[TBL] [Abstract][Full Text] [Related]
16. Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
Forst T; Bramlage P
Expert Opin Pharmacother; 2014 Jun; 15(9):1299-313. PubMed ID: 24837407
[TBL] [Abstract][Full Text] [Related]
17. The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.
Younis A; Eskenazi D; Goldkorn R; Leor J; Naftali-Shani N; Fisman EZ; Tenenbaum A; Goldenberg I; Klempfner R
Cardiovasc Diabetol; 2017 May; 16(1):69. PubMed ID: 28532406
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study.
Ji LN; Pan CY; Lu JM; Li H; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Zhang RY; Wang XL; Wang L;
Cardiovasc Diabetol; 2013 Aug; 12():118. PubMed ID: 23958390
[TBL] [Abstract][Full Text] [Related]
19. Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA.
Fofonka A; Ribeiro JP; Casali KR; Schaan BD
Trials; 2014 Nov; 15():424. PubMed ID: 25366037
[TBL] [Abstract][Full Text] [Related]
20. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors.
Aouidad I; Fite C; Marinho E; Deschamps L; Crickx B; Descamps V
JAMA Dermatol; 2013 Feb; 149(2):243-5. PubMed ID: 23426497
[No Abstract] [Full Text] [Related]
[Next] [New Search]